The researcher whose work led to migraine medicines used by millions will guide BetterLife’s headache program.

BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has formed a Scientific Advisory Board, appointing Professor Peter Goadsby as Co-Chair to guide the development of BETR-001 for chronic cluster headache and chronic migraine. Goadsby is recognized for his research on CGRP, a key driver of migraine. The company granted him stock options for 500,000 shares. BETR-001 is an investigational product not yet approved by any regulatory authority.

Original reporting
Published Oct 14, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$BETRF
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Low
01

Why it matters

The announcement adds credibility to BETR-001 development but does not provide immediate financial metrics.

02

Market read

A modest corporate development for a micro‑cap biotech; relevance confined to investors tracking early‑stage neurology therapeutics.

03

What to watch

Regulatory pathway uncertainties for LSD‑derived compounds could dampen investor enthusiasm.

Relevance 5/10Novelty 6/10Timing: today

Background

BetterLife Pharma announced a Scientific Advisory Board chaired by a renowned migraine researcher, granting him stock options.

Market effects

Potential positive signal for biotech firms developing novel migraine therapies.

Limited to Canadian biotech market; minimal broader impact.

Low; niche therapeutic area with limited immediate global market effect.

Counterpoint

The advisory board appointment may not translate into near‑term value if clinical milestones are delayed.

Key entities

  • BetterLife Pharma Inc.

    Biotech firm developing BETR-001 for chronic cluster headache and migraine.

  • Peter Goadsby, MD, PhD, FRS

    Renowned migraine researcher appointed Co‑Chair of the SAB.

Related articles

MedAI 8/10

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.

HighAI 8/10

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

$UBERMed

Kohl’s products now available for delivery on Uber Eats

Uber (UBER) and Kohl's (KSS) partnered to offer Kohl's products via Uber Eats, covering 1,100+ U.S. stores. Items include apparel, home goods, and Sephora beauty products. The service launches before the holiday season, with a $10 discount on first orders over $50 until December 3, 2026. Kohl's operates 1,100+ stores in 49 states.

$SPCBMed

SuperCom Wins 2nd Electronic Monitoring Contract in Indiana, Fully Displacing Incumbent Provider

SuperCom (SPCB) won its second electronic monitoring contract in Indiana, replacing an incumbent provider. The deal involves deploying its PureSecurity suite, with rollout starting in December 2026. The company reported a trailing twelve-month EBITDA of approximately $12.1 million through Q3 2026, citing over 50 new U.S. contracts and 20 national project wins in Europe since mid-2024.